Clinical observation on shu xin yi mai capsules for prevention of recurrent stricture after coronary artery introducing treatment.

Shu Xin Yi Mai Capsules ([symbol: see text]) combined with western medicine was used in the routine treatment of 22 cases who successfully received coronary artery introducing therapy (Chinese-western medicine group), and the results was compared with the 26 cases treated routinely with simple western medicine in the control group (western medicine group). It was found that both the recurrence rate of angina pectoris and the incidence rate of recurrent stricture in the Chinese-western medicine group were significantly lower than that in the control group (both P < 0.05). There was no significant difference between the two groups in expression of platelet activating molecules CD62P (alpha-granular membrane protein), CD63 (lysosome intact membrane protein) and CD41 (glucoprotein IIb) before the treatment, but with a significant difference after the treatment (P < 0.05).